Prospects for new drugs for chronic obstructive pulmonary disease

Lancet

Volumn 364, Issue 9438, 2004, Pages 985-996

  Barnes, Peter J ^a   Hansel, Trevor T ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; 2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY] PHENOXY]BENZOIC ACID; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ALPHA 1 ANTITRYPSIN; ANTIOXIDANT; BAYX 1005; BIIL 284; CILOMILAST; ELAFIN; ETANERCEPT; GEFITINIB; INFLIXIMAB; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; LY 29311; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MSI 1956; NIFLUMIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PYRIDINE DERIVATIVE; RECOMBINANT INTERLEUKIN 10; RESVERATROL; RETINOIC ACID; ROFLUMILAST; SB 201146; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZILEUTON;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CONFERENCE PAPER; DISEASE COURSE; DISEASE MARKER; EMPHYSEMA; ENZYME ACTIVITY; HUMAN; INFLAMMATORY CELL; LUNG FIBROSIS; LUNG PARENCHYMA; PRIORITY JOURNAL; SMOKING CESSATION; TARGET CELL;

EID: 4444280869     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)17025-6     Document Type: Conference Paper

References (119)

1. Barnes PJ. New treatments for COPD. Nat Rev Drug Discov. 1:2002;437-445
2. Hansel TT, Barnes Pj, eds. New drugs for asthma, allergy and COPD. Basel: Karger, 2001.
3. Hansel TT, Barnes PJ. An atlas of chronic obstructive pulmonary disease. 2004;Parthenon, London
4. Calverley PM, Walker P. Chronic obstructive pulmonary disease. Lancet. 362:2003;1053-1061
5. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 22:2003;672-688
6. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 163:2001;1304-1309
7. Barnes PJ. New concepts in COPD. Annu Rev Med. 54:2003;113-129
8. Shapiro SD. Animal models for COPD. Chest. 117:2000;223S-227S
9. Dawkins PA, Stockley RA. Animal models of chronic obstructive pulmonary disease. Thorax. 56:2001;972-977
10. Tashkin DP, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo controlled, randomised trial. Lancet. 357:2001;1571-1575
11. Dani JA. Roles of dopamine signaling in nicotine addiction. Mol Psychiatry. 8:2003;255-256
12. Kantak KM. Vaccines against drugs of abuse: a viable treatment option? Drugs. 63:2003;341-352
13. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management of chronic obstructive pulmonary disease. NHLBI/WHO Workshop Report 2003; www.goldcopd.com/workshop/index.html (accessed Dec 4, 2003).
14. Hansel TT, Barnes PJ. Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Today. 38:2002;585-600
15. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 years treatment with tiotropium. Eur Respir J. 19:2002;209-216
16. Rutgers SR, Postma DS, ten Hacken NH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax. 55:2000;12-18
17. Barnes PJ. Cytokine modulators as novel therapies for airway disease. Eur Respir J Suppl. 34:2001;67s-77s
18. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med. 113:2002;59-65
19. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med. 340:1999;1948-1953
20. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen T. Randomised, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease. BMJ. 320:2000;1297-1303
21. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 343:2000;1902-1909
22. Culpitt SV, Rogers DF, Shah P, et al. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 167:2003;24-31
23. Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression and inhibits glucocorticoid actions in alveolar macrophages. FASEB J. 15:2001;1100-1102
24. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet. 363:2004;731-733
25. Ito K, Lim S, Caramori G, et al. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA. 99:2002;8921-8926
26. Barnes PJ. Theophylline: new perspectives on an old drug. Am J Respir Crit Care Med. 167:2003;813-818
27. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 21:2003;74-81
28. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomoised controlled trial. Lancet. 361:2003;449-456
29. Montuschi P, Collins JV, Ciabattoni G, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med. 162:2000;1175-1177
30. Paredi P, Kharitonov SA, Leak D, Ward S, Cramer D, Barnes PJ. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 162:2000;369-373
31. Macnee W. Oxidants/antioxidants and COPD. Chest. 117:2000;303S-317S
32. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ. 322:2001;1271-1274
33. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev. 53:2001;135-159
34. Culpitt SV, Rogers DF, Fenwick PS, et al. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax. 58:2003;942-946
35. Ichinose M, Sugiura H, Yamagata S, Koarai A, Shirato K. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. Am J Respir Crit Care Med. 160:2000;701-706
36. Hansel TT, Kharitonov SA, Donnelly LE, et al. A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. FASEB J. 17:2003;1298-1300
37. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med. 160:1999;893-898
38. Montuschi P, Kharitonov SA, Ciabattoni G, Barnes PJ. Exhaled leukotrienes and prostaglandins in COPD. Thorax. 58:2003;585-588
39. Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T. A second leukotriene B4 receptor BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med. 192:2000;421-432
40. Silbaugh SA, Stengel PW, Cockerham SL, et al. Pharmacologic actions of the second generation leukotriene B4 receptor antagonist LY29311: in vivo pulmonary studies. Naunyn Schmiedebergs Arch Pharmacol. 361:2000;397-404
41. Crooks SW, Bayley DL, Hill SL, Stockley RA. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J. 15:2000;274-280
42. Beeh KM, Kornmann O, Buhl R, Culpitt SV, Giembycz MA, Barnes PJ. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest. 123:2003;1240-1247
43. Gompertz S, Stockley RA. A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest. 122:2002;289-294
44. Davenpeck KL, Berens KL, Dixon RA, Dupre B, Bochner BS. Inhibition of adhesion of human neutrophils and eosinophils to P-selectin by the sialyl Lewis antagonist TBC1269: preferential activity against neutrophil adhesion in vitro. J Allergy Clin Immunol. 105:2000;769-775
45. Noguera A, Busquets X, Sauleda J, Villaverde JM, Macnee W, Agusti AG. Expression of adhesion molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 158:1998;1664-1668
46. Hay DWP, Sarau HM. Interleukin-8 receptor antagonists in pulmonary diseases. Curr Opin Pharmacol. 1:2001;242-247
47. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 153:1996;530-534
48. Yamamoto C, Yoneda T, Yoshikawa M, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest. 112:1997;505-510
49. Yang XD, Corvalan JR, Wang P, Roy CM, Davis CG. Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J Leukoc Biol. 66:1999;401-410
50. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol. 18:2000;217-242
51. Traves SL, Culpitt S, Russell REK, Barnes PJ, Donnelly LE. Elevated levels of the chemokines GRO-α and MCP-1 in sputum samples from COPD patients. Thorax. 57:2002;590-595
52. de Boer WI, Sont JK, van Schadewijk A, Stolk J, van Krieken JH, Hiemstra PS. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol. 190:2000;619-626
53. Saetta M, Mariani M, Panina-Bordignon P, et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 165:2002;1404-1409
54. Vernooy JH, Kucukaycan M, Jacobs JA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med. 166:2002;1218-1224
55. de Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM. Elevated TNF-alpha production by peripheral blood monocytes of weight- losing COPD patients. Am J Respir Crit Care Med. 153:1996;633-637
56. Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs. 59:2000;1341-1359
57. Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs. 57:1999;945-966
58. Rabinowitz MH, Andrews RC, Becherer JD, et al. Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). J Med Chem. 44:2001;4252-4267
59. Takanashi S, Hasegawa Y, Kanehira Y, et al. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur Respir J. 14:1999;309-314
60. Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology. 119:2000;1473-1482
61. Sturton G, Fitzgerald M. Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest. 121:2002;192S-196S
62. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther. 297:2001;280-290
63. Compton CH, Gubb J, Nieman R, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet. 358:2001;265-270
64. Gamble E, Grootendorst DC, Brightling CE, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 168:2003;976-982
65. Reid P. Roflumilast. Curr Opin Investig Drugs. 3:2002;1165-1170
66. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J. 370:2003;1-18
67. Lamontagne S, Meadows E, Luk P, et al. Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. Brain Res. 920:2001;84-96
68. Robichaud A, Stamatiou PB, Jin SL, et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest. 110:2002;1045-1052
69. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci USA. 99:2002;7628-7633
70. Kuss H, Hoefgen N, Johanssen S, Kronbach T, Rundfeldt C. In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5- hydroxy-indole-3-yl]-glyo xylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration. J Pharmacol Exp Ther. 307:2003;373-385
71. Di Stefano A, Caramori G, Capelli A, et al. Increased expression of NF-κB in bronchial biopsies from smokers and patients with COPD. Eur Respir J. 20:2002;556-563
72. Caramori G, Romagnoli M, Casolari P, et al. Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax. 58:2003;348-351
73. Delhase M, Li N, Karin M. Kinase regulation in inflammatory response. Nature. 406:2000;367-368
74. Castro AC, Dang LC, Soucy F, et al. Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett. 13:2003;2419-2422
75. Nasuhara Y, Adcock IM, Catley M, Barnes PJ, Newton R. Differential IKK activation and IκBα degradation by interleukin-1β and tumor necrosis factor-α in human U937 monocytic cells: evidence for additional regulatory steps in κB-dependent transcription. J Biol Chem. 274:1999;19965-19972
76. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 298:2002;1911-1912
77. Meja KK, Seldon PM, Nasuhara Y, et al. p38 MAP kinase and MKK-1 co-operate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF-κB-independent mechanism. Br J Pharmacol. 131:2000;1143-1153
78. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov. 2:2003;717-726
79. Underwood DC, Osborn RR, Bochnowicz S, et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol. 279:2000;L895-902
80. Sasaki T, Irie-Sasaki J, Jones RG, et al. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science. 287:2000;1040-1046
81. Ward S, Sotsios Y, Dowden J, Bruce I, Finan P. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem Biol. 10:2003;207-213
82. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 391:1998;82-86
83. Patel HJ, Belvisi MG, Bishop-Bailey D, Yacoub MH, Mitchell JA. Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy. J Immunol. 170:2003;2663-2669
84. Harris SG, Phipps RP. Induction of apoptosis in mouse T cells upon peroxisome proliferator-activated receptor gamma (PPAR-γ) binding. Adv Exp Med Biol. 507:2002;421-425
85. Vestbo J. Epidemiological studies in mucus hypersecretion. Novartis Found Symp. 248:2002;3-12
86. Barnes PJ. Current and future therapies for airway mucus hypersecretion. Novartis Found Symp. 248:2002;237-249
87. Nadel JA, Burgel PR. The role of epidermal growth factor in mucus production. Curr Opin Pharmacol. 1:2001;254-258
88. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet. 361:2003;137-139
89. Zhou Y, Shapiro M, Dong Q, et al. A calcium-activated chloride channel blocker inhibits goblet cell metaplasia and mucus overproduction. Novartis Found Symp. 248:2002;150-165
90. Rogers DF. Pharmacological regulation of the neuronal control of airway mucus secretion. Curr Opin Pharmacol. 2:2002;249-255
91. de Boer WI, van Schadewijk A, Sont JK, et al. Transforming growth factor beta1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 158:1998;1951-1957
92. Takizawa H, Tanaka M, Takami K, et al. Increased expression of transforming growth factor-beta1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med. 163:2001;1476-1483
93. Dallas SL, Rosser JL, Mundy GR, Bonewald LF. Proteolysis of latent transforming growth factor-β (TGF-β)-binding protein-1 by osteoclasts: a cellular mechanism for release of TGF-β from bone matrix. J Biol Chem. 277:2002;21352-21360
94. 2-adrenoceptor gene transcription. Naunyn Schmiedebergs Arch Pharmacol. 362:2000;520-525
95. Ishikawa T, Kume H, Kondo M, Ito Y, Yamaki K, Shimokata K. Inhibitory effects of interferon-gamma on the heterologous desensitization of beta-adrenoceptors by transforming growth factor-beta 1 in tracheal smooth muscle. Clin Exp Allergy. 33:2003;808-815
96. Yakymovych I, Engstrom U, Grimsby S, Heldin CH, Souchelnytskyi S. Inhibition of transforming growth factor- β signaling by low molecular weight compounds interfering with ATP- or substrate-binding sites of the TGF β type I receptor kinase. Biochemistry. 41:2002;11000-11007
97. Miotto D, Hollenberg MD, Bunnett NW, et al. Expression of protease activated receptor-2 (PAR-2) in central airways of smokers and non-smokers. Thorax. 57:2002;146-151
98. Vliagoftis H, Schwingshackl A, Milne CD, et al. Proteinase-activated receptor-2-mediated matrix metalloproteinase-9 release from airway epithelial cells. J Allergy Clin Immunol. 106:2000;537-545
99. Frungieri MB, Weidinger S, Meineke V, Kohn FM, Mayerhofer A. Proliferative action of mast-cell tryptase is mediated by PAR2, COX2, prostaglandins, and PPARgamma: possible relevance to human fibrotic disorders. Proc Natl Acad Sci USA. 99:2002;15072-15077
100. Cocks TM, Fong B, Chow JM, et al. A protective role for protease-activated receptors in the airways. Nature. 398:1999;156-160
101. Kranenburg AR, de Boer WI, van Krieken JH, et al. Enhanced expression of fibroblast growth factors and receptor FGFR-1 during vascular remodeling in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 27:2002;517-525
102. Stockley RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med. 160:1999;S49-52
103. Shapiro SD, Senior RM. Matrix metalloproteinases: matrix degradation and more. Am J Respir Cell Mol Biol. 20:1999;1100-1102
104. Luisetti M, Travis J. Bioengineering: alpha 1-proteinase inhibitor site-specific mutagenesis: the prospect for improving the inhibitor. Chest. 110:1996;278S-283S
105. Stecenko AA, Brigham KL. Gene therapy progress and prospects: alpha-1 antitrypsin. Gene Ther. 10:2003;95-99
106. Luisetti M, Sturani C, Sella D, et al. MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur Respir J. 9:1996;1482-1486
107. Fujie K, Shinguh Y, Yamazaki A, Hatanaka H, Okamoto M, Okuhara M. Inhibition of elastase-induced acute inflammation and pulmonary emphysema in hamsters by a novel neutrophil elastase inhibitor FR901277. Inflamm Res. 48:1999;160-167
108. Leung-Toung R, Li W, Tam TF, Karimian K. Thiol-dependent enzymes and their inhibitors: a review. Curr Med Chem. 9:2002;979-1002
109. Belvisi MG, Bottomley KM. The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs? Inflamm Res. 52:2003;95-100
110. Russell RE, Culpitt SV, DeMatos C, et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 26:2002;602-609
111. Massaro G, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med. 3:1997;675-677
112. Belloni PN, Garvin L, Mao CP, Bailey-Healy I, Leaffer D. Effects of all-trans-retinoic acid in promoting alveolar repair. Chest. 117:2000;235S-241S
113. Lucey EC, Goldstein RH, Breuer R, Rexer BN, Ong DE, Snider GL. Retinoic acid does not affect alveolar septation in adult FVB mice with elastase-induced emphysema. Respiration. 70:2003;200-205
114. Mao JT, Goldin JG, Dermand J, et al. A pilot study of all-trans-retinoic acid for the treatment of human emphysema. Am J Respir Crit Care Med. 165:2002;718-723
115. Otto WR. Lung epithelial stem cells. J Pathol. 197:2002;527-535
116. Barnes PJ. Molecular genetics of chronic obstructive pulmonary disease. Thorax. 54:1999;245-252
117. Sandford AJ, Silverman EK. Chronic obstructive pulmonary disease: 1, susceptibility factors for COPD the genotype-environment interaction. Thorax. 57:2002;736-741
118. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med. 163:2001;1693-1772
119. Dowson LJ, Guest PJ, Stockley RA. Longitudinal changes in physiological, radiological, and health status measurements in α1-antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med. 164:2001;1805-1809